A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|High Grade Serous Ovarian Cancer|Endometrial Cancer
Interventions: DRUG: AO-252
Sponsor: A2A Pharmaceuticals Inc.